

# Postmeiotic Segregation Increased 2(PMS2) (PT2116) IHC kit

CatalogNo: IHCM6220

## Key Features

### Host Species

- Mouse

### Reactivity

- Human, Mouse,

### Applications

- IHC

### Isotype

- IgG1, Kappa

## Recommended Dilution Ratios

## Storage

**Storage\*** 2°C to 8°C/1 year

## Basic Information

**Clonality** Monoclonal

**Clone Number** PT2116

## Immunogen Information

**Immunogen** Synthesized peptide derived from human Postmeiotic Segregation Increased 2(PMS2) AA range: 600-700

**Specificity** The antibody can specifically recognize human PMS2 protein.

## Target Information

**Gene name** PMS2 PMSL2

**Protein Name** Postmeiotic Segregation Increased 2(PMS2)


Organism	Gene ID	UniProt ID
Human	<a href="#">5395</a> ;	<a href="#">P54278</a> ;

**Cellular Localization** Nuclear


**Tissue specificity** Amygdala,Brain,Endometrial tumor,Epithelium,Human endometri

**Function** Disease:Defects in PMS2 are a cause of mismatch repair cancer syndrome (MMRCS) [MIM:276300]; also known as Turcot syndrome and brain tumor-polyposis syndrome 1 (BTPS1). MMRCS is an autosomal dominant disorder characterized by malignant tumors of the brain associated with multiple colorectal adenomas. Skin features include sebaceous cysts, hyperpigmented and cafe au lait spots.,Disease:Defects in PMS2 are the cause of hereditary non-polyposis colorectal cancer type 4 (HNPCC4) [MIM:600259]. Mutations in more than one gene locus can be involved alone or in combination in the production of the HNPCC phenotype (also called Lynch syndrome). Most families with clinically recognized HNPCC have mutations in either MLH1 or MSH2 genes. HNPCC is an autosomal, dominantly inherited disease associated with marked increase in cancer susceptibility. It is characterized by a familial predisposition to early onset colorectal carcinoma (CRC) and extra-colonic cancers of the gastrointestinal, urological and female reproductive tracts. HNPCC is reported to be the most common form of inherited colorectal cancer in the Western world, and accounts for 15% of all colon cancers. Cancers in HNPCC originate within benign neoplastic polyps termed adenomas. Clinically, HNPCC is often divided into two subgroups. Type I: hereditary predisposition to colorectal cancer, a young age of onset, and carcinoma observed in the proximal colon. Type II: patients have an increased risk for cancers in certain tissues such as the uterus, ovary, breast, stomach, small intestine, skin, and larynx in addition to the colon. Diagnosis of classical HNPCC is based on the Amsterdam criteria: 3 or more relatives affected by colorectal cancer, one a first degree relative of the other two; 2 or more generation affected; 1 or more colorectal cancers presenting before 50 years of age; exclusion of hereditary polyposis syndromes. The term "suspected HNPCC" or "incomplete HNPCC" can be used to describe families who do not or only partially fulfill the Amsterdam criteria, but in whom a genetic basis for colon cancer is strongly suspected.,Function:Component of the post-replicative DNA mismatch repair system (MMR). Heterodimerizes with MLH1 to form MutL alpha. DNA repair is initiated by MutS alpha (MSH2-MSH6) or MutS beta (MSH2-MSH3) binding to a dsDNA mismatch, then MutL alpha is recruited to the heteroduplex. Assembly of the MutL-MutS-heteroduplex ternary complex in presence of RFC and PCNA is sufficient to activate endonuclease activity of PMS2. It introduces single-strand breaks near the mismatch and thus generates new entry points for the exonuclease EXO1 to degrade the strand containing the mismatch. DNA methylation would prevent cleavage and therefore assure that only the newly mutated DNA strand is going to be corrected. MutL alpha (MLH1-PMS2) interacts physically with the clamp loader subunits of DNA polymerase III, suggesting that it may play a role to recruit the DNA polymerase III to the site of the MMR. Also implicated in DNA damage signaling, a process which induces cell cycle arrest and can lead to apoptosis in case of major DNA damages.,similarity:Belongs to the DNA mismatch repair mutL/hexB family.,subunit:Heterodimer of PMS2 and MLH1 (MutL alpha). Forms a ternary complex with MutS alpha (MSH2-MSH6) or MutS beta (MSH2-MSH3). Part of the BRCA1-associated genome surveillance complex (BASC), which contains BRCA1, MSH2, MSH6, MLH1, ATM, BLM, PMS2 and the RAD50-MRE11-NBS1 protein complex. This association could be a dynamic process changing throughout the cell cycle and within subnuclear domains.,


## Validation Data




Human colon carcinoma tissue was stained with anti-PMS2 (PT2116) Antibody



Human colon carcinoma tissue was stained with anti-PMS2 (PT2116) Antibody



Human colon carcinoma tissue was stained with anti-PMS2 (PT2116) Antibody



Human colon carcinoma tissue was stained with anti-PMS2 (PT2116) Antibody

## Contact information

Orders: [order@immunoway.com](mailto:order@immunoway.com)  
Support: [tech@immunoway.com](mailto:tech@immunoway.com)  
Telephone: 408-747-0189 (USA) 400-8787-807(China)  
Website: <http://www.immunoway.com>  
Address: 2200 Ringwood Ave San Jose, CA 95131 USA



Please scan the QR code to access additional product information:  
**Postmeiotic Segregation Increased 2(PMS2) (PT2116) IHC kit**